Cargando…
Recombinant Activated Factor VII as a Second Line Treatment for Postpartum Hemorrhage
BACKGROUND: Severe or massive postpartum hemorrhage (PPH) has remained a leading cause of maternal mortality for decades across the world and it results in critical obstetric complications. Recombinant activated factor VII (rFVIIa) has emerged as a gold standard adjunctive hemostatic agent for the t...
Autores principales: | Park, Soon Chang, Yeom, Seok Ran, Han, Sang Kyoon, Jo, Young Mo, Kim, Hyung Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Critical Care Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786683/ https://www.ncbi.nlm.nih.gov/pubmed/31723654 http://dx.doi.org/10.4266/kjccm.2016.00787 |
Ejemplares similares
-
Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side
por: van Veen, E. J. W., et al.
Publicado: (2007) -
Treatment of obstetric hemorrhage with recombinant activated factor VII
por: Czuprynski, P, et al.
Publicado: (2009) -
Evaluation of Recombinant Factor VIIa Treatment for Massive Hemorrhage in Patients with Multiple Traumas
por: Koh, Young Rae, et al.
Publicado: (2012) -
Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis
por: Mandal, S. K., et al.
Publicado: (2012) -
A case of intracranial hemorrhage in a neonate with congenital factor VII deficiency
por: Lee, Won Seok, et al.
Publicado: (2010)